Drug Discovery Generates Good Science, Business and Drug Development
In my mind, the pharmaceutical and biotech industry can be reduced down to one elegant equation: good science + good business decisions = good drug development.
Good Science.
As the marketing director for CorDynamics, I spend a lot of my time discussing our innovative preclinical cardiovascular drug discovery and drug safety models. It’s our reason for being. My job is to communicate our capabilities and the good science we generate to clients, colleagues and potential customers.
Good Science=Good Business Decisions
As a member of the Healthcare Business Women’s—Chicago Chapter I’ve attended a number meetings led by dynamic senior healthcare and pharmaceutical executives discussing how to navigate our changing industry.
After each of these events, my underlying takeaway is that tough business decisions can be made easier when armed with good science.
When the science is solid and reliable—in our case from a cardiovascular drug discovery and drug safety side—it can be a useful guide for folks faced with extreme budget and timeline constraints.
It’s our job as the cardiovascular CRO, to understand the pressures on our clients as well as the need to be flexible, affordable and most importantly, collaborative in the work outsourced to us.
Good Science + Good Business Decisions = Good Drug Development
Earlier this year, I flew 2,000 miles to be with an aging parent undergoing surgery. I tried not to think of all the science, education and yes, business decisions that would go into this one procedure. All went well. As I headed to the pharmacy to pick up the prescriptions necessary to inspire a full recovery and greater wellness, I walked away with tangible proof of my theory.
Related Posts via Categories
- Tags:
- Cardiovascular Studies,
- Drug Discovery,
- Drug Safety,
- HBA,
- Preclinical Outsourcing,
- Preclinical Services
